Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research

Larimar Therapeutics (Nasdaq: LRMR) will present three nomlabofusp posters at the International Congress for Ataxia Research on November 12, 2026.

Rhea-AI Summary

Larimar Therapeutics (Nasdaq: LRMR) will present three nomlabofusp posters at the International Congress for Ataxia Research on November 12, 2026. The presentations cover previously disclosed interim clinical data from an ongoing open-label study of long-term daily administration, alongside new plasma lipid and gene expression analyses in participants with Friedreich’s ataxia.

All three posters are scheduled for 6:30–7:30 p.m. ET in the Poster and Exhibitor Hall (D) at the Cobb Convention Center in Atlanta. The congress runs November 10–13, 2026.

Key Terms

open-label study, friedreich’s ataxia, gene expression

3 terms

open-label study medical

"ongoing open-label study"

An open-label study is a type of research where both the participants and the researchers know which treatment or intervention is being administered. This transparency can influence the results, making it important for investors to consider potential biases or limitations when evaluating the study’s findings. Understanding this helps assess the reliability of evidence supporting new products or therapies.

friedreich’s ataxia medical

"study participants with Friedreich’s ataxia"

A hereditary neurological disorder that gradually damages the nerves controlling coordination and often affects the heart and spine; think of it as the body’s wiring slowly wearing out, leading to worsening balance, muscle weakness, and cardiac issues. It matters to investors because the absence of a widely effective cure creates demand for new drugs, diagnostics and therapies, so progress in clinical trials, regulatory decisions or treatment approvals can significantly influence biotech company value and market opportunity.

gene expression technical

"Dysregulated Gene Expression in Friedreich’s Ataxia"

Gene expression is the process by which a cell reads a gene’s instructions and produces the molecules—usually proteins—that do work in the body, like building structures or sending signals. Think of a gene as a recipe and expression as the act of cooking: whether and how much a dish gets made affects the final product. Investors care because changes in gene expression underlie diseases, treatment responses, biomarkers and drug targets, so they can influence clinical outcomes, regulatory decisions and commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich’s ataxia (FA) will be presented as part of three poster presentations at the upcoming International Congress for Ataxia Research (ICAR) 2026 being held November 10–13, 2026, in Atlanta, Georgia.

Poster Presentation Details

• Abstract Title: Long-Term Daily Nomlabofusp Administration in Patients with Friedreich’s Ataxia: Interim Observations from an Ongoing Open-Label Study
  
  
• Abstract Title: Plasma Lipid Profiles in Patients with Friedreich’s Ataxia Before and After Treatment with Nomlabofusp
  
  
• Abstract Title: Dysregulated Gene Expression in Friedreich’s Ataxia and Response to Treatment with Nomlabofusp
  
  

All three posters will be presented during the Poster Session Day 3 on Thursday, November 12, from 6:30 to 7:30 p.m. ET in the Poster and Exhibitor Hall (D) at the Cobb Convention Center.

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact: Joyce Allaire      LifeSci Advisors  jallaire@lifesciadvisors.com      (212) 915-2569

Company Contact: Michael Celano  Chief Financial Officer mcelano@larimartx.com (484) 414-2715